Bimekizumab efficacy in male and female patients with axial spondyloarthritis: 52-week results from the Phase 3 BE MOBILE rials
Clicks: 4
ID: 325165
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Emerging Content
0.9
/100
4 views
3 readers
AI Quality Assessment
Not analyzed
Readership in this journal
EmergingRanked #35 of 202 articles by views in Lara D. Veeken
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 202 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
OBJECTIVES: To assess sex-based differences in response to bimekizumab in patients with axial spondyloarthritis (axSpA) from two phase 3 trials. METHODS: Improvements to Week 52 in measures of disease activity (ASAS40, ASDAS <2.1, BASDAI) and function (BASFI), pain, fatigue, health-related quality of life (HRQoL) and objective signs of inflammation (MRI, hs-CRP) were assessed post hoc in patients with non-radiographic (nr-) and radiographic (r-)axSpA from BE MOBILE 1 (NCT03928704) and BE MOBILE 2 (NCT03928743), respectively. Comparisons were made between sexes at Week 16 (bimekizumab versus placebo treatment effect) and Week 52 (treatment response in bimekizumab-randomised patients only) using odds ratios for dichotomous outcomes and difference values for continuous outcomes. For hs-CRP, ratio to baseline was calculated due to skewed distribution. RESULTS: While sex distribution was balanced in nr-axSpA (54.3% male), 72.3% of patients with r-axSpA were male. At Week 16, bimekizumab-randomised male patients typically had better treatment responses versus placebo compared with female patients across ASAS40, ASDAS <2.1 and improvements in BASDAI, BASFI and measures of HRQoL. At Week 52, female patients had longer-term improvements across these outcomes, though male patients continued to have numerically higher treatment responses. In contrast, active inflammation (MRI, hs-CRP) was reduced to similarly low levels in both sexes at Week 16 and maintained to Week 52, despite baseline differences. CONCLUSIONS: Although male patients had earlier clinical responses to bimekizumab treatment, female patients demonstrated longer-term improvements in composite and patient-reported outcomes. Both sexes had substantial improvements in objective inflammation at Week 16 and 52, despite baseline differences. TRIAL REGISTRATION: Clinicaltrials.gov; NCT03928704 and NCT03928743.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (30 words).
Try re-searching for a better abstract.
| Reference Key |
openalex_W7203653909
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Martín Rudwaleit, Josef S Smolen, Denis Poddubnyy, Marina Magrey, Irene van der Horst‐Bruinsma, Atul Deodhar, V. Taieb, Sarah Kavanagh, Natasha de Peyrecave, Lianne S. Gensler |
| Journal | Lara D. Veeken |
| Year | 2026 |
| DOI |
10.1093/rheumatology/keag425
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.